Conjoint analysis of French and German parents' willingness to pay for meningococcal vaccine

PharmacoEconomics

Volumn 25, Issue 2, 2007, Pages 143-154

  Bishai, David ^a   Brice, Roger ^b   Girod, Isabelle ^b   Saleh, Aneta ^b   Ehreth, Jenifer ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MAPI VALUES   (United States)

^c Celgene   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; CLINICAL FEATURE; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FEMALE; FRANCE; GERMANY; HEALTH SURVEY; HUMAN; MALE; MATHEMATICAL MODEL; MENINGOCOCCEMIA; PARENT COUNSELING; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCHOOL CHILD;

ADOLESCENT; ADULT; DATA INTERPRETATION, STATISTICAL; FEMALE; FRANCE; GERMANY; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; PARENTS; PATIENT EDUCATION; PATIENT SATISFACTION; PRESCRIPTION FEES; VIDEOTAPE RECORDING;

EID: 33846647872     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725020-00006     Document Type: Review

References (30)

1. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001 May 3; 344 (18): 1378-88
2. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004 Dec; 23 (12 Suppl.): S274-9
3. Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ 2002 Apr 6; 324 (7341): 809
4. Fergus S, Zimmerman MA. Adolescent resilience: a framework for understanding healthy development in the face of risk. Annu Rev Public Health 2004 Oct 26; 26: 399-419
5. Welte R, Trotter CL, Edmunds WJ, et al. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics 2005; 23 (9): 855-74
6. Jackson LA, Schuchat A, Gorsky RD, et al. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health 1995 Jun; 85 (6): 843-5
7. Viscusi WK. The value of risks to life and health. J Econ Lit 1993; 31: 1912-46
8. Shepard CW, Ortega-Sanchez IR, Scott RD, et al. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005 May; 115 (5): 1220-32
9. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2005 May 27; 54 (RR-7): 1-21
10. Bridges JF. Future challenges for the economic evaluation of healthcare: patient preferences, risk attitudes and beyond. Pharmacoeconomics 2005; 23 (4): 317-21
11. Trotter CL, Edmunds WJ. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Making 2006 Jan-Feb; 26 (1): 38-47
12. Prosser LA, Bridges CB, Uyeki TM, et al. Values for preventing influenza-related morbidity and vaccine adverse events in children. Health Qual Life Outcomes 2005; 3 (1): 18
13. Prosser LA, Ray GT, O'Brien M, et al. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 2004 Feb; 113 (2): 283-90
14. Pauly MV. Valuing health care benefits in money terms. In: Sloan F, editor. Valuing health care. Cambridge: Cambridge University Press, 1996
15. Vogt F, Schwappach DL, Bridges JF. Accounting for tastes: a German perspective on the inclusion of patient preferences in healthcare. Pharmacoeconomics 2006; 24 (5): 419-23
16. Ryan M, Gerard K. Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy 2003; 2 (1): 55-64
17. Ryan M, Bate A, Eastmond CJ, et al. Use of discrete choice experiments to elicit preferences. Qual Health Care 2001 Sep; 10 Suppl. 1: i55-60
18. Eppright DR, Hunt JB, Tanner JF, et al. Fear, coping, and information: a pilot study on motivating a healthy response. Health Mark Q 2002; 20 (1): 51-73
19. Janis I, Feshbach S. Effects of fear-arousing communications. J Abnorm Soc Psychol 1953; 48 (1): 78-92
20. ABC News. Campus killer. 20/20 [aired 1999 Sep 17]. New York: ABC, 1999
21. Louviere JJ. Analyzing decision-making: metric conjoint analysis. London: Sage Publications, 1988
22. Sawtooth Software Inc. The CBC system user's manual. Evanston (IL): Sawtooth Technologies, 1999
23. Huber J, Zwerina K. The importance of utility balance in efficient choice designs. J Mark Res 1996; 33: 307-17
24. Chrzan K. An overview and comparison of design strategies for choice-based conjoint analysis. Sequim (WA): Sawtooth Software Inc., 2000
25. Miguel FS, Ryan M, Amaya-Amaya M. 'Irrational' stated preferences: a quantitative and qualitative investigation. Health Econ 2005 Mar; 14 (3): 307-22
26. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 1980; 48 (4): 817-38
27. Rabe-Hesketh S, Skrondal A. Reliable estimation of generalized linear mixed models using adaptive quadrature. Stata J 2002; 2 (1): 1-21
28. Hausman JA. Specification tests in econometrics. Econometrica 1978; 46 (6): 1251-71
29. National Conference of State Legislatures. Meningitis laws by state [online]. Available from URL: http://www.ncsl.org/programs/health/meningitisleg. htm [Accessed 2006 Dec 4]
30. Rajecki DW. Persuasive communication and attitudes: attitudes. Sunderland (MA): Sinauer Associates, 1990